Document is current
Any future updates will be listed below
-
Authors
Imaizumi, Takahiro
Hamano, Takayuki
Fujii, Naohiko
Huang, Jing
Xie, Dawei
Ricardo, Ana C.
He, Jiang
Soliman, Elsayed Z.
Kusek, John W.
Nessel, Lisa
Yang, Wei
Maruyama, Shoichi
Fukagawa, Masafumi
Feldman, Harold I.
,
Appel, Lawrence J.
Go, Alan S.
Lash, James P.
Nelson, Robert G.
Rahman, Mahboob
Rao, Panduranga S.
Shah, Vallabh O.
Townsend, Raymond R.
Unruh, Mark L.
- License Information
-
More Information
Article History
Received: 21 September 2020
Revised: 12 November 2020
Accepted: 26 November 2020
First Online: 22 January 2021
Compliance with ethical standards
:
: The CKD-JAC Study was financially supported by Kyowa Kirin Company (KKC). The funding agencies had no role in the study design; collection, analysis, or interpretation of data; or decision to submit the report for publication. Advisory role: HF (Kyowa Kirin Company);Honoraria: TI, TH, LN, and SM (Kyowa Kirin Company), NF (Kyowa Kirin Company, Chugai, Torii Pharmaceutical, Baxter and Ono Pharmaceutical), MF (Kyowa Kirin Company, Ono-Pharmaceutical, Kissei Pharmaceutical, Bayer Yakuhin, Ono Pharmaceutical, and Torii Pharmaceutical), and HF (Kyowa Kirin Company and InMed, Inc.) All remaining authors have nothing to disclose.
